3篇
您的检索式：作者名="Robin L.Jones"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Dermatofibrosarcoma protuberans: from translocation to targeted therapy显示文摘Dermatofibrosarcoma protuberans(DFSP), the most common dermal sarcoma, is a low-grade, slow growing fibroblastic malignant neoplasm that most frequently affects middle aged adults and is characterized by a high local recurrence rate and a low propensity for metastasis. Wide surgical resection or Mohs micrographic surgery(MMS) are the preferred approaches for localized disease, while radiation therapy is warranted for inoperable disease or for cases with positive margins where re-excision is not possible. DFSP is generally regarded as refractory to conventional chemotherapy. Treatment options for systemic disease were limited until the discovery of a unique translocation, t(17;22)(q22;q13)(COL1A1;PDGFB) found in a majority of cases. In recent years, imatinib, a PDGFβR, ABL and KIT inhibitor, has revolutionized systemic therapy in DFSP. In this review, we summarize the epidemiological, clinical, histological and genetic characteristics of DFSP and update the readers on its current management. | Jonathan Noujaim Khin Thway Cyril Fisher Robin L.Jones | 2015 | Cancer Biology & Medicine2015，12，4： | 4 |
| 2 | Recent advances in the systemic treatment of gastrointestinal stromal tumors显示文摘Historical overview of the treatment for advanced gastrointestinal stromal tumors(GISTs)GISTs represent a relatively rare entity;however,GISTs are still the most common mesenchymal neoplasm in the gastrointestinal tract.The majority of GISTs express the transmembrane receptor,KIT,a product of the KIT proto-oncogene that can lead to uncontrolled cell proliferation and resistance to apoptosis1-3. | Robin L.Jones Marin Golcic | 2023 | Cancer Biology & Medicine2023，20，10： | 0 |
| 3 | Pazopanib in advanced soft tissue sarcomas显示文摘Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma(STS).Initially developed as a small molecule inhibitor of vascular endothelial growth factor receptors,preclinical work indicates that pazopanib exerts an anticancer effect through the inhibition of both angiogenic and oncogenic signaling pathways.Following the establishment of optimal dosing and safety profiles in early phase studies and approval for the treatment of advanced renal cell carcinoma,pazopanib was investigated in STS.A landmark phase III randomized study demonstrated improved progression-free survival with pazopanib compared to that with placebo in pretreated patients with STS of various subtypes.The efficacy of pazopanib in specific STS subtypes has been further described in real-world-based case series in both mixed and subtype-specific STS cohorts.At present,there are no clinically validated predictive biomarkers for use in selecting patients with advanced STS for pazopanib therapy,limiting the clinical effectiveness and cost-effectiveness of the drug.In this review,we summarize the preclinical and clinical data for pazopanib,outline the evidence base for its effect in STS and explore reported studies that have investigated putative biomarkers. | Alex T.J.Lee Robin L.Jones Paul H.Huang | 2019 | Signal Transduction and Targeted Therapy2019，4，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员